KR890014128A - 황산염화된 k5 항원 및 황산염화된 k5 항원 단편물 - Google Patents

황산염화된 k5 항원 및 황산염화된 k5 항원 단편물 Download PDF

Info

Publication number
KR890014128A
KR890014128A KR1019890002884A KR890002884A KR890014128A KR 890014128 A KR890014128 A KR 890014128A KR 1019890002884 A KR1019890002884 A KR 1019890002884A KR 890002884 A KR890002884 A KR 890002884A KR 890014128 A KR890014128 A KR 890014128A
Authority
KR
South Korea
Prior art keywords
antigen
sulfated
compound according
fragment
preparing
Prior art date
Application number
KR1019890002884A
Other languages
English (en)
Inventor
아드리안 안톤 반 뵈켈 콘스탄트
윌렘 카렐 반 데뎀 기이스베르트
안나 크라예벨트 닐트예
Original Assignee
에프.지.엠.헤르만스.에이.디. 도우마
악조엔.브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.지.엠.헤르만스.에이.디. 도우마, 악조엔.브이 filed Critical 에프.지.엠.헤르만스.에이.디. 도우마
Publication of KR890014128A publication Critical patent/KR890014128A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음.

Description

황산염화된 K5 항원 및 황산염화된 K5 항원 단편물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 적어도 3개의 단당체 유닛 및 그것의 염을 포함하는 황산염화된 K5 항원 및 황산염화된 K5 항원 단편물.
  2. 제1항에 있어서, 적어도 4개의 단당체 유닛을 포함하는 것을 특징으로 하는 화합물.
  3. 제1항 또는 2항에 있어서, 적어도 5개의 단당체 유닛을 포함하는 것을 특징으로 하는 화합물.
  4. 제1항 내지 3항중 어느 한항에 있어서, 단당체 유닛당 황산염기의 평균수가 적어도 0.01인 것을 특징으로 하는 화합물.
  5. 제1항 내지 4항중 어느 한항에 있어서, 단당체 유닛당 황산염기의 평균수가 0.25내기 1인 것을 특징으로 나는 화합물.
  6. 적어도 3개의 당유닛을 포함하는 K5항원 및/혹은 K5 항원 단편물을 황산염화하는 것을 특징으로 하는, 제1항의 화합물을 제조하는 방법.
  7. 황산염화된 K5 항원을 단편화하는 것을 특징으로 하는 제1항의 황산화된 K5 항원 단편물을 제조하는 방법.
  8. 글루코사민 유닛의 위치(2)에서 아민기를 포함하고 있는 황산염화된 K5 항원 단편물을 선택적으로 아세틸화하는 것을 특징으로 하는 제1항의 황산염화된 K5 항원 단편물을 제조하는 방법.
  9. 유효성분으로서 제1항 내지 5항중 어느 한항의 화합물을 하나 혹은 그 이상 포함하는 약학적 제제.
  10. 비환원 말단에 탄소원자 4 및 5 사이에 이중결합을 가지고 탄소원자 4에 히드록실기를 가지지 않은 글루큐론산을 포함하고, 상기 비환원 말단에 상기 4-OH 기가 수소원자로 치환된 글루큐론산을 포함하고, 상기 비 환원 말단에 글루코사민을 포함하는 혹은 상기 아노머 말단의 알데하이드기가 환원된 K5 황원 단편물.
  11. 4급 암모니움염을 사용하여 상기 K5 항원을 침전시키고, 이 수득한 침전물로부터 염을 사용하여 K5 항원을 추출하고 연속적으로 그것을 정제함으로써 K5 항원을 소유하는 박테리아 함유 액체로부터 K5 항원을 분리하는 방법에 있어서, 4급 암모니움 염을 사용한 침전에 선행하여 액체 1리터당 50 내지 250g의 또다른 염을 사용하여 처리하는 것을 특징으로 하는 방법.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019890002884A 1988-03-10 1989-03-09 황산염화된 k5 항원 및 황산염화된 k5 항원 단편물 KR890014128A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8800597 1988-03-10
NL8800597 1988-03-10

Publications (1)

Publication Number Publication Date
KR890014128A true KR890014128A (ko) 1989-10-21

Family

ID=19851917

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890002884A KR890014128A (ko) 1988-03-10 1989-03-09 황산염화된 k5 항원 및 황산염화된 k5 항원 단편물

Country Status (10)

Country Link
US (1) US5071969A (ko)
EP (1) EP0333243A3 (ko)
JP (1) JPH01282201A (ko)
KR (1) KR890014128A (ko)
AU (1) AU609586B2 (ko)
DK (1) DK115189A (ko)
FI (1) FI891131A (ko)
NZ (1) NZ228271A (ko)
PT (1) PT89958A (ko)
ZA (1) ZA891502B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0798588B2 (ja) * 1986-10-13 1995-10-25 ニチデン機械株式会社 リ−ドフレ−ム分離装置
DK0454220T3 (da) * 1990-04-23 1993-11-22 Sanofi Elf Carbohydratderivater omfattende en trisaccharidenhed
FR2669932B1 (fr) * 1990-12-03 1994-07-01 Sanofi Sa Nouvel heparosane-n,o-sulfate, son procede de preparation et les compositions pharmaceutiques qui le contiennent.
GB2286193A (en) * 1991-03-28 1995-08-09 Italfarmaco Spa Anticoagulants and processes for preparing such
FR2684385B1 (fr) * 1991-11-28 1997-08-01 Sanofi Elf Heparosanes-n,o-sulfates de haute masse moleculaire, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2687686B1 (fr) * 1992-02-26 1994-05-27 Sanofi Elf Enzyme destinee a la fragmentation du n-acetylheparosane, obtention des preparations contenant cette enzyme et procedes de fragmentation utilisant cette enzyme.
DE4312476A1 (de) * 1993-04-16 1994-10-20 Kolbus Gmbh & Co Kg Vorrichtung zum Vereinzeln von Bogen eines Bogenstapels
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
IT1289613B1 (it) * 1997-02-07 1998-10-15 Inalco Spa Polisaccaridi batterici o-solfatati
IT1290814B1 (it) * 1997-03-24 1998-12-11 Istituto Scient Di Chimica E B Glicosaminoglicani aventi elevata attivita' antitrombotica
ITMI991465A1 (it) * 1999-07-02 2001-01-02 Inalco Spa Processo per la preparazione dei polisaccaridi k4 e k5 da escherichiacoli
WO2003022860A1 (en) 2001-09-07 2003-03-20 Alchemia Pty Ltd Synthetic heparin pentasaccharides
US20120253029A1 (en) 2002-06-18 2012-10-04 Pasqua Anna Oreste Process for the preparation of highly o-sulfated epimerized derivatives of k5 polysaccharide and intermediates therein
CN1671744A (zh) * 2002-06-18 2005-09-21 格利考斯2000有限公司 低分子量过硫酸化多糖
JP2006291102A (ja) * 2005-04-13 2006-10-26 National Institute Of Advanced Industrial & Technology 精製オリゴ糖画分
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
FR2949114B1 (fr) * 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3265781D1 (en) * 1981-05-21 1985-10-03 Akzo Nv New anti-thromboticum based on polysacharides, method for its preparation and pharmaceutical compositions
GB2128617A (en) * 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
EP0158291A3 (en) * 1984-04-10 1988-07-27 Takeda Chemical Industries, Ltd. A method for purifying carcinoembryonic antigen and a method for producing a carcinoembryonic antigen-reactive monoclonal antibody
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
EP0300099A1 (en) * 1987-07-20 1989-01-25 Akzo N.V. New pentasaccharides

Also Published As

Publication number Publication date
AU3090189A (en) 1989-09-21
FI891131A (fi) 1989-09-11
DK115189D0 (da) 1989-03-09
DK115189A (da) 1989-09-11
FI891131A0 (fi) 1989-03-09
ZA891502B (en) 1989-11-29
NZ228271A (en) 1991-05-28
EP0333243A3 (en) 1989-09-27
PT89958A (pt) 1989-11-10
AU609586B2 (en) 1991-05-02
EP0333243A2 (en) 1989-09-20
US5071969A (en) 1991-12-10
JPH01282201A (ja) 1989-11-14

Similar Documents

Publication Publication Date Title
KR890014128A (ko) 황산염화된 k5 항원 및 황산염화된 k5 항원 단편물
Orgueira et al. Modular synthesis of heparin oligosaccharides
Leach Release and breakdown of sialic acid from human salivary mucin and its role in the formation of dental plaque
Wieruszeski et al. Structure of the monosialyl oligosaccharides derived from salivary gland mucin glycoproteins of the Chinese swiftlet (genus Collocalia). Characterization of novel types of extended core structure, Gal beta (1—3)[GlcNAc beta (1—6)] GalNAc alpha (1—3) GalNAc (-ol), and of chain termination,[Gal alpha (1—4)] 0-1 [Gal beta (1—4)] 2GlcNAc beta (1—.).
Andersson et al. Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells.
French Chemical and physical properties of fructans
DK179882A (da) Oligosakkarider med selektiv antikoagulationsvirkning
Kim et al. Effect of electron-withdrawing protecting groups at remote positions of donors on glycosylation stereochemistry
KR830007077A (ko) 악타플라닌의 가비당체의 제조방법
EP0319253A3 (en) Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
ATE246455T1 (de) Kohlenhydratmischung
FR2684385B1 (fr) Heparosanes-n,o-sulfates de haute masse moleculaire, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR920701249A (ko) 글리코실화 인슐린
Antonopoulos et al. Isolation and identification of the glycosaminoglycans from fracture callus
Roy et al. Efficient synthesis of α (2–8)-linked N-acetyl and N-glycolylneuraminic acid disaccharides from colominic acid
KR950008528A (ko) 두개의 당류와 하나의 스페이서(spacer)를 함유하는 이결합체
Shaw et al. Structural Studies on the O‐Antigen of Aeromonas salmonicida
Heidelberger et al. Relations between structures of three K polysaccharides of Escherichia coli and cross-reactivity in antipneumococcal sera
FR2570081B1 (fr) Polysaccharides membranaires utiles notamment comme medicament et procede pour leur preparation
ES2010972T3 (es) Metodo para la preparacion de lactulosa cristalina de alta pureza y el producto obtenido.
KR880013877A (ko) 비천연형 세라미드 관련화합물 및 그 제조법
KR840005463A (ko) Omt의 c-23-변형유도체의 제조방법
BR9706398A (pt) Genes da rafinose sintese e seu uso.
GB1426910A (en) 3-deoxy derivatives of neamine and its related aminoglycosidic antibiotics and the production thereof
Heidelberger et al. Inhibition by aldobiouronates in the precipitation of pneumococcal type II and III systems

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid